In last trading session, AIM ImmunoTech Inc (AMEX:AIM) saw 0.49 million shares changing hands with its beta currently measuring -0.38. Company’s recent per share price level of $0.30 trading at $0.01 or 4.48% at ring of the bell on the day assigns it a market valuation of $17.31M. That closing price of AIM’s stock is at a discount of -133.33% from its 52-week high price of $0.70 and is indicating a premium of 16.67% from its 52-week low price of $0.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.31 million shares which gives us an average trading volume of 281.59K if we extend that period to 3-months.
For AIM ImmunoTech Inc (AIM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.12 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
AIM ImmunoTech Inc (AMEX:AIM) trade information
Upright in the green during last session for gaining 4.48%, in the last five days AIM remained trading in the green while hitting it’s week-highest on Thursday, 08/15/24 when the stock touched $0.30 price level, adding 4.76% to its value on the day. AIM ImmunoTech Inc’s shares saw a change of -31.14% in year-to-date performance and have moved 14.52% in past 5-day. AIM ImmunoTech Inc (AMEX:AIM) showed a performance of -21.12% in past 30-days. Number of shares sold short was 0.63 million shares which calculate 2.91 days to cover the short interests.
AIM ImmunoTech Inc (AIM) estimates and forecasts
This year revenue growth is estimated to fall -35.60% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10k for the same. And 3 analysts are in estimates of company making revenue of 40k in the next quarter. Company posted 46k and 65k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 42.86% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 28.89% while estimates for its earnings growth in next 5 years are of 25.00%.
AIM ImmunoTech Inc (AMEX:AIM)’s Major holders
Insiders are in possession of 8.96% of company’s total shares while institution are holding 14.63 percent of that, with stock having share float percentage of 16.07%. Investors also watch the number of corporate investors in a company very closely, which is 14.63% institutions for AIM ImmunoTech Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at AIM for having 1.99 million shares of worth $0.94 million. And as of 2024-03-31, it was holding 4.0501 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 0.7 million shares on 2024-03-31. The number of shares represents firm’s hold over 1.4222 of outstanding shares, having a total worth of $0.33 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2024 , the former fund manager was holding 1.31 shares of worth $0.4 million or 2.30% of the total outstanding shares. The later fund manager was in possession of 620.23 shares on Mar 31, 2024 , making its stake of worth around $0.19 million in the company or a holder of 1.09% of company’s stock.
